Lead-212 PSV359 Therapy for Patients With Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Original English text from ClinicalTrials.gov
Trial details
- Minimum age
- 18 Years
- Maximum age
- 90 Years
- Last updated (source)
- July 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (11)
University of Miami
Miami, United States
Biogenix
Miami, United States
University of Kansas
Kansas City, United States
University of Kentucky
Lexington, United States
Mayo Clinic in Rochester, Minnesota
Rochester, United States
Saint Louis University
St Louis, United States
Nebraska Cancer Specialists
Omaha, United States
Ohio State University
Columbus, United States
University of Pittsburgh Medical Center
Pittsburgh, United States
MD Anderson Cancer Center
Houston, United States
University of Wisconsin
Madison, United States
Trial contact
ClinicalTrials at Perspectivetherapeutics
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.